Pacira BioSciences (PCRX) Research & Development (2010 - 2026)

Pacira BioSciences' Research & Development history runs 17 years deep, the most recent figure standing at $28.1 million for Q1 2026.

• On a quarterly basis, Research & Development rose 10.77% year-over-year to $28.1 million in Q1 2026; TTM through Mar 2026 was $119.7 million, a 34.97% increase from a year earlier, with the FY2025 full-year figure at $117.3 million, up 43.81% from the prior year.
• Research & Development fell to $28.1 million in Q1 2026 per PCRX's latest filing, from $37.5 million in the prior quarter.
• Across five years, Research & Development topped out at $37.5 million in Q4 2025 and bottomed at $17.1 million in Q1 2023.
• The 5-year median for Research & Development is $20.8 million (2023), against an average of $22.8 million.
• Across the five-year window, Research & Development soared 109.04% in 2022 and slipped 28.38% in 2023, its largest moves.
• Year by year, Research & Development stood at $17.5 million in 2022, then climbed by 11.19% to $19.5 million in 2023, then increased by 22.78% to $23.9 million in 2024, then surged by 56.73% to $37.5 million in 2025, then dropped by 25.05% to $28.1 million in 2026.
• Per Business Quant, the three latest PCRX Research & Development figures stand at $28.1 million (Q1 2026), $37.5 million (Q4 2025), and $26.0 million (Q3 2025).